Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma

Recruiting now · Not applicable

Conditions studied: Thyroid Neoplasms, Carcinoma, Papillary

In brief

This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.

Key facts

Study ID

NCT07033572

Run by

Fujian Medical University

People needed

60

Starts

2018-06-01

Expected to finish

2028-06-30

Last updated by the study team

2025-07-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-65 years.
• Dominant-side PTC ≤1.5 cm suitable for endoscopic resection.
• Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule.
• No radiologic lymph-node metastasis on contralateral side.
• Written informed consent.

You may not qualify if…

• Extrathyroidal extension, gross nodal or distant metastasis.
• Prior neck surgery, prior RFA/ethanol injection, or neck irradiation.
• Pregnancy or lactation.
• Serious comorbidities precluding anesthesia or follow-up.

Where it is running

• Fujian Medical University Union Hospital — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.